The effects of the neuroleptic flupenthixol on the expression of the genes coding for the mitochondrial ubiquinone and cytochrome b 5 reductases have been studied because of the importance of these enzymes in energy metabolism, oxidative stress and also because similar but oppositely directed changes have been previously observed in the cerebral cortex from schizophrenics. The neuroleptic flupenthixol reduces the expression in rats of the gene coding for NADH-cytochrome b 5 reductase as measured by in situ hybridisation and its enzymic manifestation. Flupenthixol also reduces the enzymic activity of the mitochondrial NADHubiquinone reductase, and it has been previously shown that mRNA from the mitochondrially coded parts of the enzyme are reduced by the drug. Both the cis-and therapeutically less active trans-flupenthixol were found to produce these changes in rats. Post-mortem brain tissue from schizophrenics who have received neuroleptic medication have reduced levels of both reductases as measured enzymically, Lymphocyte samples from schizophrenics also have reduced levels of both reductases compared with normals. The superoxide anion O − 2 is the principle agent of oxidative stress and both the cytochrome b 5 and the ubiquinone reductase enzymes were semi-purified from sheep liver and shown to produce appreciable amounts of superoxide. Superoxide production is reduced in brain homogenates from rats treated with flupenthixol. Its production is also reduced in brain tissue and lymphocytes from schizophrenics receiving neuroleptic medication. We conclude that neuroleptic medication reduces the expression of both the ubiquinone and cytochrome b 5 reductase and among the effects of this reduction is a decrease in the production of neurotoxic superoxide.
Introduction
Schizophrenia is characterised by delusional experiences and thought disorder with a lifetime morbidity of the order of 1%. Studies on the biological basis of the psychoses have turned up many sometimes contradictory clues but the substantive aetiological theories result from the effects of drugs which afford some measure of symptomatic relief. Hence the 'dopaminergic' hypothesis of schizophrenia because neuroleptic medications are found to affect various parts of the dopamine neurotransmitter system. Despite intensive investigation the 'dopamine' hypothesis has not been found to be particularly predictive and in particular there is 1 Liability to schizophrenia is partially inherited. Calculations from twin and family studies indicate that approximately 60-70% of the risk is inherited. A fairly intensive study of those parts of the human genome that code for dopamine receptors and related enzymes has not so far revealed a linkage that is reproducible under extended scrutiny. 2, 3 A linkage study covering the whole nuclear coded genome at an average 9 cM intervals has revealed about 25 loci linked to schizophrenia 4 with probabilities greater than P Ͻ 0.05, but there does not appear to be any functional connection between these loci.
An alternative approach is to try and find out which genes are expressed differently in patients suffering from psychosis. We characterised the mRNA from postmortem brain of schizophrenics and normals by 2-D translational analysis to establish that it was not so degraded as to confound the whole approach. [5] [6] [7] The mRNA populations in post-mortem brain of schizophrenics were then compared to normals by differen-tial screening, a protocol that allows the identification of genes whose relative transcript levels are altered between two tissue types. 8 Five clones were selected as being differentially expressed in schizophrenics and were then found to be derived from mitochondrial (mt)DNA; four of these were for ribosomal RNA but an upregulated clone coding for cytochrome oxidase subunit II was also found. 9 Neuroleptic medication is known to cause changes in gene expression in brain, 10 and in parallel studies it was found that cis(␣)-flupenthixol by comparison with its therapeutically inactive isomer trans(␤)-fluphenthixol caused the differential expression in rat brain of 29 clones, 14 of which were of mitochondrial origin (S Jones, personal communication and Whatley et al 11 ). Predominant among the mitochondrial sequences were those coding for cytochrome oxidase subunits I and II and the NADH-ubiquinone reductase, all of which were downregulated by cis-flupenthixol. Expression of the nuclear gene coding for NADH-cytochrome b 5 reductase was also found to be downregulated by cisflupenthixol.
There is therefore an apparent involvement of the processes of mitochondrial oxidative energy metabolism in the aetiology of schizophrenia and an effect of neuroleptic medication on the same processes. An additional issue is that both the ubiquinone and the b 5 reductase enzymes are flavoproteins that while mediating the transfer of electrons from NAD(P)H are known to produce small amounts of superoxide which has been invoked as an aggravating or even causal factor in neurotoxicity and mental illness. 12 To study this, a simple method of measuring superoxide production has been devised and applied to the brain samples.
In this investigation we seek to relate the amounts of the reductases in brain and lymphocyte tissues from schizophrenics, the extent to which any changes might be due to neuroleptic medication and the role both play in the production of toxic superoxide.
Preliminary studies 11 of the activity of the two reductase enzymes suggested that in the brains of schizophrenic patients either the respiratory chain (ubiquinone) reductase activity was decreased with a compensating increase in the outer membrane (b 5 ) reductase or that there was a change in the properties of ubiquinone reductase in schizophrenics such that it is less sensitive to rotenone. In order to distinguish and measure the two reductases correctly in small amounts of tissue we have investigated the properties of the semi-purified enzymes and applied improved methods so that rotenone sensitivity of the ubiquinone reductase from schizophrenics can be independently monitored to resolve this question.
Methods

Human brain tissue
This was obtained from frontal cortex obtained post-mortem from 10 normals, 15 schizophrenic patients of which five had not received medication within 4 weeks of death. Of the brain samples 24 were from the MRC Brain Bank, Newcastle General Hospital and a further three schizophrenic and three normal samples were provided from the Institute of Psychiatry brain bank. The sample set is described in Table 1 . Because of varying tissue availability the same samples were not always used in each study. Diagnosis of the patients was carried out by means of DSM-III. Death was at average age of 65.7 × 16 years (normals) and 70.6 ± 10 years (schizophrenics) and was from various causes. The post-mortem delay ranged from 3 to 84 hours with averages of 25.6 ± 13 (normals) and 69.4 ± 3.3 (schizophrenics) and 41.2 ± 16.8 (unmedicated schizophrenics). Because of the rather higher post-mortem delay for the schizophrenic cohort a sub-group with shorter post-mortem delay (39.2 ± 6.7 n = 5) was identified and the results of enzyme assays and superoxide production calculated separately. In no case was there a significant difference between the results from the short and long post-mortem delay subgroups.
Human lymphocytes These were obtained from normals and male patients admitted to the hospital wing of Broadmoor. Lymphocytes were isolated from an 8-ml whole blood sample by the technique of Boyum.
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Diagnosis of these patients was carried out by means of DSM-III and the sample set is described in Table 2 . All tissue was stored at −70°C until use.
Enzyme preparations NADH ubiquinone and cytochrome b 5 reductases and cytochrome b 5 itself were made from 66 g fresh sheep liver following the general procedure described by Yang and Cederbaum.
14 The tissue was homogenised in 600 ml 0.25 M sucrose buffered with 10 mM Tris-Cl pH 7.4 and 1.0 mM EDTA. The nuclear fraction was removed as a pellet after centrifugation twice at 500 g for 10 min. Mitochondria were sedimented at 11 000 g for 16 min and washed twice with 20 volumes sucrose buffer. The mitochondrial fraction was frozen in aliquots and used without further treatment except for dilution to 0.85 g protein l −1 as a source of NADH-ubiquinone reductase. Each microgram of protein in the preparation was derived from 0.26 mg tissue.
Polyethylene glycol (PEG average molecular wt 6000) was added to the post-mitochondrial supernatant to a final concentration of 8.5% and spun at 13 000 g for 20 min. The microsomal pellet was washed twice with 60 ml PEG-sucrose. The washed pellet was resuspended in 100 ml (ie approximately 8 mg protein ml −1 ) of 0.1 M Tris-acetate pH 8.1 containing 1 mM EDTA, 1 mM phenylmethyl sulphonyl fluoride and 2% final concentration Triton X-100 and stirred for 1 h. After centrifugation at 13 000 g for 25 min, the supernatant was taken for chromatography onto 20 g DEAE cellulose in a 400 mm × 20 mm column equilibrated with 80 mM Tris-acetate buffer pH 8.1 containing 1 mM EDTA and 2% Triton X-100. After charging the column it was eluted with the Tris-acetate buffer. NADH-ferricyanide reductase activity was assayed in the eluate and the peak fractions (282-561 ml) pooled to consti- tute the source of NADH-cytochrome b 5 reductase. After a further 100 ml of elution with the Tris-acetate buffer NASCN (90 mM) was added to it, the Tris being correspondingly reduced to 10 mM and elution continued with a further 360 ml. This eluate constituted the source of cytochrome b 5 . Both eluates from the column were dialysed with three changes against 2 L of water. Triton X-100 was removed by treatment with 100 g Amberlite XAD previously washed with two changes of methanol and four changes of water. The solutions were lyophilised and reconstituted as required to give suspensions (20-fold concentration) containing 0.12 g protein l −1 of the reductase and 0.3 g l −1 of the cytochrome. Each microgram of the reductase was derived from 40.2 mg of tissue and 1 g of the cytochrome was derived from 1.46 mg of tissue. All preparations were kept at −70°C.
In situ hybridisation Rat brain sections (20 m) were fixed for 1 min in 4% paraformaldehyde and acetylated for 1 min in 0.1 M triethanolamine containing 0.9% (v/v) NaCl, pH 8.0, and 0.25% (v/v) acetic anhydride. Sections were then washed for 1 min in PBS and dehydrated in 70%, 80% and 90% ethanol (v/v). After dehydration, delipidation in chloroform for 1 min was performed followed by rehydration in 100% and 95% ethanol (v/v). The sections were stored at −20°C. Four picomoles of specific oligonucleotide probes were end-labelled using terminal transferase (25 U l −1 , Promega, UK) at 37°C for 1 h with 40 pmol 35 S dATP (1200 Ci mmol −1 , Dupont, UK) and unincorporated bases removed using Nunctrap push columns (Dupont). The probes were then resuspended in hybridisation buffer (4 × SSC, 50% (v/v) formamide, 1× Denhart's solution, 20 mM sodium phosphate, 10% (w/v) dextran sulphate, 100 g ml −1 salmon sperm DNA, yeast tRNA, polyadenylic acid and 1% (w/v) dithiothreitol) to an activity of 1 × 10 7 cpm per 90 l. Sections were then incubated overnight at 40°C in a chamber humidified with hydridisation buffer. Following hybridisation, sections were washed in 1 × SSC (150 mM NaCl, 15 mM sodium citrate) for 4 × 15 min at 35°C, followed by two 60-min washes at room temperature, and were allowed to dry in air. Exposure to autoradiographic film (Hyperfilm-3 H, Amersham, UK) was between 10-15 days and the resulting autoradio- graphs were hard-developed using Kodak D19 developer, fixed and then dried. The level of non-specific hybridisation was assessed by pretreatment with RNAses (60 mg ml −1 ) at 37°C overnight, prior to hybridisation and competition with 200-fold excess of unlabelled oligonucleotide probe. The relative integrated grey values (IGV) were determined by comparison in the linear range with a 14 C autoradiograph standard supplied by Amersham UK. Background IGV values were taken immediately adjacent to the tissue section.
Ubiquinone and cytochrome b 5 reductase assay These were usually carried out at 25°C in 20 mM KPi buffer pH 7.4 containing 1 mM EDTA using NAD(P)H at a final concentration of 100 M. The change in absorbance with time at 420 nm (ferricyanide), 600 nm (dichlorindophenol DCIP) and 550 nm (cytochrome c) were monitored. The rate of decrease of NAD(P)H absorbance changes at 340 nm was also used to verify the activity of the ferricyanide, DCIP and cytochrome c reductases. The concentrations of acceptors were ferricyanide 1.0 mM, DCIP 100 M and cytochrome c 80 M. The b 5 reductase does not directly transfer electrons to cytochrome c so cytochrome b 5 was added to a final concentration of 0.6 g ml −1 to act as a catalyst when cytochrome c was used as an acceptor. NADH-ubiquinone reductase activity was measured by following the rate of decrease in absorbance change at 340 nm following the addition Table 3 (671/270 = 2.48).
Superoxide This was measured by its ability to reduce nitro-tetrazolium blue to an insoluble bluebrown formazan using a modification of the method of Beauchamp and Fridovich. 15 The formazan was filtered off in the wells of a 'dot-blot' manifold onto glass-fibre filter paper and after drying was quantitated with a Logitech hand-held scanner. The darkness of the deposits was estimated using Quantiscan software. Superoxide decomposes rapidly in aqueous solution but is slightly soluble and relatively stable in dimethylsulphoxide (DMSO). Solid potassium superoxide (approx 100 mg) was introduced into 1 ml BDH Analar grade DMSO triturated and then spun down in a microfuge to clear particulate matter from the supernatant. Twenty microlitres of the clear supernatant reproducibly reduced 2.7 nmoles of cytochrome c and gave a blue-brown precipitate from nitro-tetrazolium blue having an integrated grey value (IGV) of 660. A standard curve is shown in Figure 1 .
The detailed procedure for measurement of superoxide production in biological samples was as follows; enzyme or biological material was introduced into 200 l of Tris buffer pH 7.4 containing 1 mM EDTA, 1 mM CN − and 100 M NAD(P)H. Two microlitres of a stock 10 mM solution of nitro-tetrazolium in dimethylformamide was added and a 20-l sample was taken for the initial reading followed by others at 1-min intervals. These were pipetted into the wells of the filter manifold and immediately washed with 200 l phosphate buffered saline. After drying the filters were stable for about 12 h, the integrated grey value (IGV) of the spot was determined by scanning and the whole procedure was found to be sufficiently reproducible to apply the factor 0.24
Lipid peroxides Lipid peroxides were measured by the thiobarbituric acid procedure of Aust. 16 Thiobarbituric acid (0.375%) and 15% trichloracetic acid were dissolved in 0.25 M HCl. One hundred microlitres of this solution and 10 l of a 10% homogenate of frontal cortex were heated in a microfuge tube for 10 min in a boiling water bath. Four hundred microlitres of water were added and this solution was centrifuged and the optical density of the supernatant measured at 532 nm. The procedure was standardised with malondialdehyde and found to be linear in the range 0.1-10 nmoles with a blank value about 50 pmol. 
Statistics given are SEM with n = between 3 and 5. The action of inhibitors is expressed as a percentage of matched controls. ndi = no detectable inhibition. Concentrations of inhibitors were: rotenone 20 M, SOD (superoxide dismutase) 100 units ml Protein Protein was measured by the method of Bradford. 17 
Results
Properties of the ubiquinone and cytochrome b 5 reductases
In order to select optimum conditions for measurement of the two reductases in samples containing mixtures of both which had also been frozen and thawed, the two enzymes were semi-purified from a sample of fresh sheep's liver and then frozen and thawed to mimic the treatment of the brain fractions. The ubiquinone reductase being essentially a mitochondrial fraction will contain that component of the b 5 reductase known to be bound to mitochondria 18 but the b 5 reductase should not be appreciably contaminated by the ubiquinone reductase. Table 3 gives the results of a comparison of the two preparations with various donors, acceptors and inhibitors. As has been reported by Yang and Cederbaum, cytochrome b 5 is required for the optimum transfer of electrons to cytochrome c by the b 5 reductase, similarly the activity with NADH as electron donor is greater than with NADPH and the activity with FeCl 3 as acceptor is greater than with DCIP or cytochrome c. One molecule of NADH reduced only one Fe 3+ ion whereas two molecules of DCIP were reduced. The most discriminatory donor-acceptor combination for the ubiquinone reductase was NADH-CoQ 1 and for the b 5 reductase was NADPH-DCIP and NADPH-cyt c; these donor-acceptor couples were used in subsequent studies of the distribution of the two reductases.
Rotenone showed a consistent inhibition of the ubiquinone reductase at about 60-70% of control and a somewhat variable effect on the b 5 reductase showing hardly any inhibition with cyt c, FeCl 3 or CoQ 1 but a significant inhibition with DCIP as acceptor.
Chlorpromazine as has been reported previously showed a weak inhibitory effect on both reductases. 19, 20 Cis-flupenthixol which is a more powerful neuroleptic also had a pronounced inhibitory effect on the b 5 reductase.
A number of other substances variously reported as reductase inhibitors were investigated to see if any specificity they had could be usefully employed to distinguish between the two enzymes. The following inhibited the b 5 reductase at the concentrations mentioned but did not show any specificity: rhein (9,10-dihydro-9,10-dioxo-2-anthracene carboxylic acid; 20 M, 62% of control); spiperone phthalein 100 M; chrysophanic acid (1,8-dihydroxy-3-methyl-9,10-anthracenedione 100 M); dicoumarol 100 M; propylthiouracil 100 M.
In connection with a study of superoxide production by these enzymes the effect of superoxide dismutase on the utilisation of NAD(P)H and the reduction of FeCl 3 reduction of DCIP was investigated. As Table 3 shows the dismutase caused a significant reduction in the amount of product formed by the b 5 reductase.
Superoxide production
The formazan method for detecting superoxide production is more sensitive and therefore requires less tissue, also since the rate constant of the reaction of O − 2 is faster with tetrazolium than cytochrome c the fraction of superoxide captured before its spontaneous dissipation is greater, therefore the method is in principle more accurate. In Figure 1 it can be seen that while superoxide dismutase (10 units ml −1 ) readily prevents the reduction of cytochrome c 21 it hardly affects the production of formazan. The explanation for this is that whereas the capture of the superoxide ion by the dismutase is faster than its reaction with cytochrome c is not so fast as the reaction with nitro-tetrazolium in a homogeneous system. In experiments in which superoxide was formed slowly by an enzymic reaction (see Table 3 ), formazan production was variously attenuated by superoxide dismutase.
It is recognised that this attempt at quantitation assumes that the capture of superoxide by nitro-tetrazolium is sufficiently fast that competing processes do not cause appreciable losses and that NAD(P)H does not produce tetrazolium reducing materials other than by donating electrons to oxygen. The latter assumption has been checked (see Table 4 ) by carrying out the reaction anaerobically; it can be seen that oxygen is necessary for the reduction of nitro-tetrazolium by NADH and the b 5 reductase. Also shown in Figure 1 (c) is a timing curve for the production of formazan by reductase, it can be seen that the reaction rate flattens off appreciably after about 5 min. The rates quoted in Table 4 are taken over the first minute of the reaction and therefore approximate to the initial rate in the sense used in enzymic kinetics.
The substrates of the b 5 reductase (cytochrome, FeCl 3 and DCIP) all reduce the amount of formazan product. Since these substances are not inhibitors of the enzymic activity per se (Table 3 ) they must act by either being an alternative to oxygen as a sink for electrons from NADH or by being directly reduced by O − 2 . Superoxide directly reduces cytochrome c and FeCl 3 but it does not reduce DCIP in the absence of enzyme (Table 4) , so one must conclude that in this case superoxide is an intermediate in the electron transfer processes mediated by the NAD(P)H oxido-reductases. This would also be consistent with the inhibitory effect of superoxide dismutase on the reductases noted in Table 3 . 5 reductase These were investigated by submit- 21 ting laboratory rats to a protocol of flupenthixol administration designed to mimic the regimen administered to psychotic patients (1 mg kg −1 ip daily for 3 weeks). The animals were then killed within 24 h of the last injection and fresh frozen slices of brain cortex taken for in situ hybridisation with a cDNA probe that identified either the b 5 reductase or COX mRNAs. The remaining tissue was retained for measurements of superoxide production activity and ubiquinone and b 5 reductase activity. The results of in situ hybridisation with several probes in the frontal cortex are given in Table 5 . There were highly significant reductions in expression of the mRNA coding for cytochrome b 5 reductase in both cis and trans-FPT treated animals in the frontal cortex. The specificity of this effect is shown by the data for the expression of the nuclear coded gene for cytochrome oxidase subunit IV and for the mitochondrially coded gene for cytochrome oxidase subunit II. The expression of neither was much affected by cis-or trans-flupenthixol.
Neuroleptic effects on the expression of NADH-cytochrome b
The enzymic activity of the reductases was measured in the same samples with results shown in Table 6 . The changes paralleled those found in the mRNA distribution. Both cis-and trans-flupenthixol chronically administered cause decreases in both the ubiquinone and cytochrome b 5 reductase in rat frontal cortex although with only the latter enzyme was the effect statistically significant. The flupenthixols also caused a significant decrease in the capacity of the tissue to produce superoxide anion. These decreases are unlikely to be caused by residual flupenthixol in the brain homogenates (estimated maximum conc. 1 M) because its effects in vitro (see Tables 3 and 4) would not be sufficient to account for the effects shown in Table 6 .
The subcellular distribution of these activities is also shown in Table 6 . As would be expected the ubiquinone reductase is principally in the mitochondrial fraction whereas the b 5 reductase is found about equally in both mitochrondrial and supernatant fractions. Superoxide production is found mainly in the mitochondria. Table 7 are shown the results of measurements of the reductase enzymes in homogenates of frontal cortex tissue obtained postmortem from normals and schizophrenics, some of Results given are the mean integrated grey value (IGV) ± SEM (n = 5) after background subtraction. Enzyme activities and superoxide production were measured in a 10% homogenate of brain tissue. Statistic given is SEM (n = 4), * P Ͻ 0.05, ** P Ͻ 0.01. Dosage of flupenthixol was 1 mg kg −1 given daily for 3 weeks; estimated brain concentration approximately 10 M. 20 M concentration is sufficient to inhibit purified enzyme about 10-20% (see Table 2 ). Washed mitochondrial and supernatant fractions were made as described in the Methods section except that the post-mitochondrial supernatant was taken as 'supernatant' without precipitation with PEG. Ubiquinone reductase was measured as the rate of reduction in optical density at 340 nm of an 0.1 mM NADH solution in a KPi buffer solution pH 8.3 at room temperature with 0.1 mM CoQ 1 as acceptor. Cytochrome b 5 reductase was measured as the rate of reduction in optical density at 340 nm of an 0.1 mM NADPH solution in KPi buffer solution pH 8.3 at room temperature using cytochrome b 5 (concn 0.6 g l −1 ) as the acceptor in the presence of 8.3 M cytochrome c. whom had not received medication. Also shown as data in parentheses are the results when the short delay post-mortem group of schizophrenics is calculated separately. The top half of the table shows the activities measured using donor-acceptor couples specific for the two enzymes. There was a significant decrease in the cytochrome b 5 reductase in the tissue from medicated schizophrenics. Unmedicated schizophrenics showed an intermediate value so we are inclined to attribute the decrease to the effects of neuroleptic medication which was usually a flupenthixol congener.
Reductase activity in brain samples from normal and schizophrenic patients In
When the distinction between the enzymes was made on the basis of rotenone sensitivity (bottom half of Table 7 ), the changes approximate to those found in our previous study 11 in that the activity of NADH cytochrome b 5 reductase appeared to be higher in samples from schizophrenic brain compared with normals. The inhibitory effect of rotenone is thought to reside wihin the electron transport chain at Complex I whose enzymic manifestation is the NADH-ubiquinone reductase. Reductase activity that was not inhibited by rotenone was ascribed to the NAD(P)H-cytochrome b 5 reductase. However as was noted at the time, the sensitivity of the ubiquinone reductase to inhibition by rotenone might itself be changed in the schizophrenic condition. The results of the bottom and top half of Statistic given is SEM with n = 10 for normals and schizophrenics and n = 5 for unmedicated schizophrenics. Table 7 taken together suggest that in schizophrenics the ubiquinone reductase is indeed less sensitive to inhibition by rotenone. The short post-mortem delay group of schizophrenics did not show values appreciably different from the whole cohort.
Superoxide formation and lipoperoxidation
Superoxide formation and lipid peroxidation in homogenates of post-mortem frontal cortex from normals and schizophrenics is shown in Table 8 . Superoxide production is slightly but significantly lower in schizophrenics than normals whereas lipid peroxide concentrations are higher. The reduced capacity to produce superoxide would be expected to be the result of neuroleptic-induced decrease in the amounts of the reductase enzymes. The amounts of lipid peroxide will result from the immediate pre-history of oxidative stress which is not easily assessable in our sample, though it has been reported that patients taking pheno- thiazine medication have elevated concentrations of lipid peroxides in the cerebrospinal fluid. 22 Reductase activity and superoxide production in lymphocytes In order to see whether the pattern of these changes was specific to brain or could be found elsewhere in the body, lymphocyte samples were obtained from a set of male schizophrenic patients and compared with lymphocytes from normal males and females. Reductase activity and superoxide production in lymphocytes from these patients and normals are shown in Table 9 . The general pattern in lymphocytes is similar to brain; those from schizophrenic patients show a much reduced ubiquinone and b 5 reductase activity. Superoxide production is also much reduced in the schizophrenic patients all of whom were being treated with neuroleptics.
Discussion
In this study we have shown that neuroleptics as exemplified by flupenthixol repress the expression of the nuclear gene that codes for the enzyme NADH-cytochrome b 5 reductase. The related enzyme NADHubiquinone reductase which contains both mitochondrially and nuclear coded subunits is known to be decreased by neuroleptics, 23, 24 and is also decreased in Parkinson's disease. 25 The decrease in cytochrome b 5 reductase has been shown at the mRNA level in rats by in situ hybridisation (Table 5) and at the enzymic level also in rat brain (Table 6 ). In humans we find that post-mortem brain tissue (Table 7) and lymphocytes (Table 9 ) from schizophrenics have reduced levels and since these patients have received neuroleptic medication (often fluphenthixol itself), we believe the reduction is an effect of the drug rather than the illness. The data we present from the small group of unmedicated patients available to us approximates more to the normals than the schizophrenics supporting this conclusion. There are differences in the post-mortem delays experienced by our normal and schizophrenic samples but no significant differences in enzyme activity or superoxide production were found when the schizophrenic group was subdivided into those experiencing long and short post-mortem delays. Therefore we believe that the human results are not a post-mortem artefact and that as in animals flupenthixol reduces the expression of the cytochrome b 5 and ubiquinone reductase.
The major problem encountered in this study was discriminating between the two reductases when measurements have to be made (as here) on crude tissue extracts. Using semi-purified enzymes, an attempt was made to find more specific or effective inhibitors than rotenone, or combinations of electron donors and acceptors that distinguish the reductases. The inhibitory activity of rotenone is sensitive to various factors including freezing and thawing and other treatments expected to derange the lipid environment of the enzyme. 26 No very satisfactory differential inhibitors were found and the best strategy that emerged was to identify the ubiquinone reductase with the NADH-CoQ 1 couple and the b 5 reductase with the NADPH-cytochrome c couple with additions of trace amounts of cytochrome b 5 as catalyst.
The criteria of sensitivity to rotenone inhibition to distinguish ubiquinone reductase or Complex I activity is widely used but does not correlate well with distinctions based on donor and acceptor specificity in brain ( Table 7) . The discrepancy between the two methods of measurement invites the overall interpretation that there is a real decrease in the cytochrome b 5 reductase activity in schizophrenics due to their neuroleptic medication as would be expected from the animal studies and that the apparent decrease in ubiquinone reductase activity is due to a decrease in rotenone sensitivity either arising from the illness itself or a differential response to the freezing and thawing that necessarily arises from the use of post-mortem tissue.
The mechanism by which flupenthixol causes its effects on the expression of reductases is not known but we have no evidence to exclude its anti-dopamine receptor activity as being a stage in the causal sequence probably mediated via cyclic AMP effects on glucose metabolism at the 6-phosphofructo-1-kinase control point. 27, 28 In the animal studies we have not observed differences between cis-and trans-flupenthixol in experiments on mRNA, reductase activity or superoxide production (Tables 5 and 6 ). It is claimed that therapeutic efficiency of flupenthixol in humans is restricted to the cis isomer though the concentration differential is very variable (compare the studies of Johnstone et al, 1 Miller et al 29 
with Jenner and Marsden 30
). Because we have not observed stereospecificity in rats it might be argued that the effects we have observed bear no relation to the therapeutic modus operandi of neuroleptics in humans. However in view of the uncertainties in concentration dependence and species sensitivity we believe an agnostic stance to be more appropriate.
The NADH-cytochrome b 5 reductase is present on the outer membrane of mitochondria and also on the endoplasmic reticulum. In the former situation it is thought to mediate an alternative pathway of electrons from extra-mitochondrial NADH via cytochrome b 5 to cytochrome c 31 while in the latter position it is involved in drug metabolism. It is deficient in hereditary methaemoglobinurea 32 causing mental and neurological impairment.
The ubiquinone and b 5 reductase are both flavoproteins which as a class are well known under certain conditions to transfer univalent electrons to oxygen to yield superoxide (reviewed in 33 ). It is evident that the oxygen accepts electrons from the reduced flavin group directly to form superoxide. Oxygen can be viewed as but one of many alternative electron acceptors. Superoxide being extremely reactive has the capability of transferring electrons to other acceptors or undergoing self dismutation. This explains the inhibition of both reductases by superoxide dismutase when their activity is measured with the usual electron acceptors ie FeCl 3 or DCIP (Table 3 ) and the inhibitory effect of these substances when O − 2 production is measured ( Table 4 ). The inhibitory effect of the neuroleptic chlorpromazine on the b 5 reductase was noted in an earlier study and is extended here by our observations on flupenthixol. Our results suggest that these substances can accept electrons in competition with oxygen and therefore reduce the production of superoxide and inhibit reductase activity measured with other electron acceptors. There is also the possibility that neuroleptics react directly with superoxide.
The decrease in superoxide production caused by neuroleptics in animal and human brain and lymphocyte tissue in vitro is very marked (Tables 6, 8 and 9) and can reach 50%. From Table 3 and Table 7 it can be inferred that the overall ability to produce superoxide is approximately the same for both the ubiquinone and the cytochrome b 5 reductase. Since both enzymes are downregulated by neuroleptics it seems likely that they are the causal link connecting the decrease in superoxide production by the drugs. Their effect on superoxide production is quantitatively not negligible and considering the toxicity of superoxide 12 we suggest that this result reveals an important facet of neuroleptic medication. It has been reported 34 that neuroleptics increase the amounts of manganese-superoxide dismutase in the brain of psychotics. It is possible that this effect contributes to the diminution of superoxide that we have observed on flupenthixol treatment although it would not account for the changes in reductase activity.
In conclusion we have observed that the neuroleptic flupenthixol causes a downregulation of the NADHcytochrome b 5 reductase as well as the mitochondrial ubiquinone reductase and as a consequence a reduction in the brain production of neurotoxic superoxide. In our earlier studies we found that the changes in gene expression wrought by flupenthixol are in the opposite direction to those found in schizophrenia. This suggests that the action of neuroleptics in reversing oxidative stress might also play a part in reversing the pathogenesis of schizophrenia. Studies currently underway with a larger group of unmedicated schizophrenics might illuminate this possibility.
